ATOM vs NBIX · rev $135.0K vs P/E 45, rev $2.36B
Atomera Inc (ATOM) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Atomera Inc (ATOM) is a semiconductor equipment & materials company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ATOM revenue for 2024-12-31 was $135.0K. Net income was -$18.4M. Revenue was down 75.5% from 2023-12-31 to 2024-12-31. ATOM currently screens at market cap $341.1M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
ATOM currently screens at market cap $341.1M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the ATOM and NBIX stock pages for the full models.
Not investment advice.